What it sells
Biotech developing iPS-cell-derived oocyte and ovarian somatic cells for fertility treatment (pipelines DIOS-001 and DIOS-101).
Business model breakdown
Trigger: what makes them buy now?
Age-related decline in egg and sperm function lowering pregnancy odds; DIOS-001 targets better pregnancy rate through in-vitro oocyte maturation.
Workflow: what inputs become what output?
Directed differentiation of iPS cells into oocytes and ovarian somatic cells for infertility solutions.
Distribution: how it reaches customers
Pre-commercial; contact form, investors listed (ANRI, etc.); Nature-published technology and own patent.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-06-12 | Series A | 10億円超 | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.